-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 T/7RmXSHaqNjJbwBMQEE+DtW6I0ZlDOEaF6rnauBrn0LqDBsl/Eadwssyhtuv/zj
 JpewUeoaymyq4aXyr55CBg==

<SEC-DOCUMENT>0000950123-09-005041.txt : 20090713
<SEC-HEADER>0000950123-09-005041.hdr.sgml : 20090713
<ACCEPTANCE-DATETIME>20090320132153
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-09-005041
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20090320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
<TITLE>LETTER TO THE S.E.C.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="y75427cy7542701.gif" alt="(NOVOGEN LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">March&nbsp;20, 2009
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">U.S. Securities and Exchange Commission<BR>
100 F Street, N.E.<BR>
Washington, D.C. 20549

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Re:</TD>
    <TD>&nbsp;</TD>
    <TD>Novogen Limited<br>
Form&nbsp;20-F for the fiscal year ended June&nbsp;30, 2008<br> File No.&nbsp;000-29962</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is the response of Novogen Limited (the &#147;Company&#148;) to the comment set forth
in the letter, dated February&nbsp;24, 2009, from the staff (the
&#147;Staff&#148;) of the U.S. Securities and
Exchange Commission (the &#147;SEC&#148;) with respect to the Company&#146;s Annual Report on Form <BR>
20-F for
the fiscal year ended June&nbsp;30, 2008 (File No.&nbsp;000-29962).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set forth below is the Staff&#146;s comment in italics followed by the Company&#146;s response.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><I>Item&nbsp;4. Information on the Company, page 15</I> </U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I><U>Business Overview, page 15 </U></I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I><U>Licensing Arrangements, page 24</U></I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>1. We note your description of a license agreement with Archer Daniels Midland Company.
Please revise your disclosure to include a description of the material terms of this
agreement, including the term and termination provisions and aggregate potential milestone
payments. We note that in connection with this license, the company received royalty payments
from ADM of A$ 1.4&nbsp;million and A$ 1.7&nbsp;million for the fiscal years 2008 and 2007,
respectively. Please include this contract in your description of material contracts under
Item&nbsp;10 of your Form <BR>
20-F and file this agreement as an exhibit to your Form 20-F or provide
us with an analysis supporting your determination that this contract is not material to your
business.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><b>Response:</b> The following reflects the revised disclosure requested by Comment 1. The Company
respectfully requests that it be permitted to include the following disclosure in its Annual
Report on Form 20-F for the fiscal year ended June&nbsp;30, 2009 rather than amend its Annual
Report on Form 20-F for the fiscal year ended June&nbsp;30, 2008 to include such disclosure.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1997, the Company granted an exclusive royalty-bearing license, with the right to
grant sublicenses, to Protein Technologies International, then a subsidiary of Ralston Purina
Company (&#147;PTI&#148;), covering three of the Company&#146;s patent applications (and U.S. patents arising
from such applications) for the development and commercialization of prescription and
non-prescription drug products and dietary health supplements in which the biologically active
component is derived from soy and consists of at least one isoflavone covered by one of the
licensed patent applications (or U.S. patents arising from such applications). Subsequent to
the Company&#146;s grant of the license, U.S. patents were issued for all three
patent applications. The geographical territory of the license is worldwide, with the
exception of Australia and New Zealand. In 1997, Dupont acquired PTI and PTI subsequently
changed its name to Solae LLC (&#147;Solae&#148;) in connection with a joint venture
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 10pt">that it entered into with Bunge Ltd. In 2004, the parties amended the license to revise the
schedule of minimum annual payments and to provide for payment to be made by Solae to the Company
in the event that Solae sells its isoflavone drug program. The license was transferred to Archer
Daniels Midland Company (&#147;ADM&#148;) in 2005.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of the transfer, ADM assumes the rights and obligations formally held by
Solae, including the obligation to make minimum annual payments and royalty payments to the
Company. Notwithstanding the transfer of the license agreement, Solae remains obligated to make
payment to the Company in the event that Solae sells its isoflavone drug program. The license
agreement will terminate upon the expiration or invalidation of the last of the patent
applications and/or patent rights that it covers. In connection with
the license agreement, the Company
received royalty payments from ADM of A$l.4&nbsp;million and A$1.7&nbsp;million in fiscal years 2008 and
2007, respectively.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">***
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has filed an Application for Confidential Treatment with respect to certain
portions of the (i)&nbsp;Patent License Agreement, dated as of November&nbsp;13, 1997, by and among Novogen
Limited, Novogen Research Pty Limited, and Novogen Inc. (the &#147;Novogen Group&#148;) and Protein Technologies
International Inc. (the &#147;License Agreement&#148;) and (ii)&nbsp;Amendment to the Patent License Agreement,
dated as of June&nbsp;21, 2004 by and among Novogen Limited, Novogen Research Pty Limited, Novogen Inc.
and Solae LLC (formerly known as Protein Technologies International
Inc.) (the &#147;Amendment&#148;). In
connection with the Application for Confidential Treatment, the Company filed an amendment
to its Annual Report on Form 20-F for the fiscal year ended June&nbsp;30, 2008 on March
20, 2009 to add the License Agreement and the Amendment as Exhibit&nbsp;4.10 and Exhibit&nbsp;4.11,
respectively. Certain portions of Exhibit&nbsp;4.10 and Exhibit&nbsp;4.11 filed with the amendment have been
omitted pursuant to the request for Confidential Treatment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges that:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company is responsible for the adequacy and accuracy of the
disclosure in the filings;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Staff comments or changes to disclosure in response to Staff comments do not
foreclose the SEC from taking any action with respect to the filing; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company may not assert Staff comments as a defence in any
proceeding initiated
by the SEC or any person under the federal securities laws of the United States.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Sincerely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">NOVOGEN LIMITED</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ David Seaton</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">David Seaton</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>y75427cy7542701.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y75427cy7542701.gif
M1TE&.#EAQP!+`.8``+.QKME6=^>MN=I)9>GHY=JJLOGX]_SR].JWPN)+;?KZ
M^;-F<?WX^D5S:?S\_'9R</S]^/C\^?K]_.67I_7U\]>7H?C;XNO`R-?9U?;4
MV\O)QMF(F/ON\<=5;<=E=_[Z^__\_.6+F,E;<]-YBOWU]_7Z^#UK8_/,TH>$
M@\+`OM5C>=R1G?KF[=53:_OK[8!]>_7Y]./BX-Q2</'Q[YJ7E<MWA7.1A$%N
M9]5K@/W^_M)07O[^^^1NAME-;DU.3>?;V-)29?W^^_#%SM_"P]Y[D/[]_9NO
MIXVHG?KBY\S7R_W\_>K,SM/1SO/J[]B!CKG-Q._W],QK@:)Z>[2\N-Q/9DYS
M;$IY;\Y+9,Z+E%=W<,-P?8^+B=O>V=_JY9^>G/3@X>SN[&>!>?;FY]%8;_G[
M^\-?;MY@>\76SU1L:3`T,\J`C$AF7:BFHMI;=-=RB(*=CH24C&!;6962D/?W
M]M!.;NA=?=UAE=)_E\I97S=%1>"AJ\Y?=&QG9?_^_O[^_O___R'Y!```````
M+`````#'`$L```?_@'^"@X2%AH>(B8=^?PH.C(J1DI.4E9:7F)F:FX9^CT4S
MD)RCI*6FIZB7#JLI"JFOL+&RLX5^?@H/#K2[O+V^B7Y%#@]<?GU]MK_*R\R<
MGA\E-E,4'Q]%$LW9VMN=9!\P;V$S"A\.V-SHZ;^WT$=H7F0&Y>KT];(2(`9'
M65E=#M7V`@H<Y2<""`5&JF2!TZ4(B!PY_B0;2+$B(C\Y'.R84J7*&C@S/DB(
M6*2(Q9,H)3KH\Z1*`Q-HGI20,#*ES8HY\)VQTJ"!E3!/(M`T=K-H/0?>,(3Q
MV>!&F"0P<A`U2K72,4''^EC*>I404@9<;/2\T:#*4S+!CMG2ZDS4LF1=_S'%
M)<56*UM)4D&`..:PB%2O$?_\Q5JR,$V:$$!(^`#F3=F>96U@(/=A1P0'(!1!
M@##XSUP))12I#0*ADH0@J'<H(H/-8:(^AV,?WNMGQXZ:.0755IT(M3&3GCW?
M592WB"V'?3H+#NQ6N%J($(/X_0#E2$?(5K)()G?;=>\@;J\RPG@.4=8=02H%
MD3H1D80B?>`7NIL<NGV(:FW_A:@[OB);OQ$R522_8205?.WQQ96```93F'%_
M,#"'$5;PY%.%:-B0A`.%*?%:5H(,AI&#P%UDUW"BZ568(BJB&!Q67,68G#'H
MP:<51,;X]Z%6;HFB'"(YU61('RHB2(A]?>D%PO]T9#Q1X9,5^F1#%SE8XZ%Y
M);$UTG@2!*,7<3!20F21BGRPI"0R<M6E<8F!`,E(\66VHV`AYNB'!&0$=LB-
M1:"VWH">N:D;38%QA9%$MH@D#!=/]A0E3W!`\8$2Y2T""7E2B6?+2.P=26AS
M!-K"GVX`0M3E6BBREULB[RV)#T:HL:;;?XS0)(@#2O051`1_-1>?'Q#LP``#
M.T"0UB#(?+J*<2!4XZP$$0@E`:7"=)&%3S=DJ^T-54QA@#F*<.K'0^:L5!*T
M$9#!H4,`2G28K)/X009K-)443(,YI1M!'PP4TN4'GL@F&V;6=`GM9C/ENQH9
M?T0KB!(D<'"`Q`KH.9__5D&0P`(+!T`01%QW1EME-1&S8,')2'!L`*]D/%2$
M$E#84.$-)FS;4Q88E&!Q+7DJP0`)#%R30Q\%DQ'!!R20<(`+'#!]`-"3KDJ@
M`](ZH$#2!SR=-=0Y&.U'OX20,RP#"I1=]F9H,U!-P-%"8``YE$:@2`G_O"T(
M`T-@@<4*%7RQ)*@2Y6#`$"NL@,`'?T`X*)X_NY!!`5C4H,7D6M10@1`LD&"F
M!+B2D1!/VV;;0!9A=%$ISTI\@8``0Y``T<M%*&``"18(H0<6:E2.A1X"9.`"
MV;K0*I$"#!Q0NP!Z5%`X[PB<D,$!##B06"$<9""$$"=DK_WVSA^0P\NL*;`$
M__8G6*"$W*P:;P$2C#!0@`<=J%"&``=(=,@J"N@APA@KD/"(*/$A0Q$.((0-
M>*`,>^A`!T3`0!%TH`QJ0``2%*6$$ISA6I!I"LUZ4@4`H`]()'B?""K`@6OX
MQ0$DR(`>M%"&!>ZA@7M0010V(`0.R"D1Q@D&!TZ@AQK`CX$+5&`9HE"#"0B!
M!+8IQ!+4$`4<1,$#4(RB%-7P!74QX'LNT`(4HT#"TQ7"`4NTG$E(H`<9)"`!
M,L#!$A3`")`AQ0`3"(`,0B"2SOBA&F(H0!3H0(<>R*`./`BD&=J0@`'0001W
M^((!7N8`,"R%+&,1'5G"P(1VA2D82!A!"V1P`1(H@/\U)2`!`MP0@!;(\8]U
M2*4,>M"#,2R@;TJX2XY(Q2\"K"`*'>BC#/ZX2S3V@`Y7H$,-EK"K0EP`!P'P
M8R]9><8SRF`$%K#B'5E0!E8&8`^':U=S0"`$#[0A!+J`8P\2T,H$;(`%>;)&
MB/#T`05,0`8M6(%(:F,@/+%@!2J@`Q#VH(8"9"!E2,@`X?;0@BL`@0@GB-X`
MWP`ZFMFL+$>8@S!L@1DE<*@$%Q@#$%30!`88@&XN$(`9_"@"-U1``,ZSGA[N
M,`:-CH$(&?#?][XWHB+L@`,7<$(+Z+!`DQ9```BX@``J$#D/T"&12!'0!<RP
M2BQ4X*E/W8!4I5H`,0@#5TK_:$(I@=""%A#!`H_016D(`8*,SC&<$QCG&#J0
M@#8(('J/")$Y/A"!=\93,7W8040RP@$][`&>*IB`!4B0*Y/X00DN&.48=``$
M:'X@!PQPDA5H5C-M88<)N#+.8BB5@SE,H`5C`"<#YD4"`8B`"G38PPI.X`*@
MX>H#!V"!'KS9`BK<P0)!HY9?[IC8/0#A"B(80>^>IC:2.4X`PG5=\'0C!#,,
MH`XQ31K6LD9=,_E%"5D-`!"`,`8JC$$/UI#*6)%E5G#^`8YFY(%.>X"##-11
M.,*@JUU7@-<@?.(#%XA"*7$@`!<\#1L`<L"P,N`$C7:@`BR``&/"T%#+6L$$
M/8'#_QS"BQD3BL$-`]C#!910#@9<H(5CB`+]@,8`SN2`P[#-@"83<.`#."('
MK@+!`02`AQ9D>`6#-<"PP@N"GQ7/OYLID40NT(8!F,$"?D*-V<HVK,P<-KM=
M'<,5VB"")02MQX4H0D:I$(+2P#$`YA2"&_RX`1?P2B*,E"\\Z2N!/@2!<Q_X
M@A/HD``5((`#:NO:(#`2+0-DP`W<+0,"_!<!(V3!H9"\P8.SE04N,*"P()CK
M4GO@!/8%PP(C^.7\#E`-TD2+4SEPVPF(D``Z")H$(Q$&&1BP!`^8,0$30`(#
M(A`:\D!K/<*`0+2"@+@]9U0'9D`"VA!6@F*70"\\PJY6-_\9@C%3`0M(<%.O
M!Z'E[FX`K<G<``<$T`89C.&MT`D&KNI*A;NV&0*K""$A>S`!#J`[2'LN`AF*
M?0`$=.`*`W#"%SBC%`V*KJ$^,0*'(5"2G)!@`ST(0`$8`!L&",",+4#P:70M
MLHS0A&H,0$``!G`%?>>I#])S@1-T0$XBN.`#$"@!%.0Z$FB!L@3[`IMNB+Q1
M,2A)+[;!.;+_@-5ETZ%Y>_"N'CC@@)U5FPI.P'8/-L``)&Q@#`%P0P88@*[X
MUG7->/6$$EB@21FH(`,*&$I[)$+URW"`"%=(P!Z&4((/4``.:VA*S;`U]P:$
M@0`@@,"T5F&!/=0Y`P*4`!)(307_#\14"?8M>H-L0?42W),*&;Z``Z13)03@
M`?)1R$"NX(WF')HJ!V_6T<S;T`(<V/SF9JK&7MCR9*T"H0.=G``0$H"#"R@@
M-&3=LGF_O'3B9:`&=!C#!%A0A'3!^>KF/L:T,A#T,6#A`$+)E)#[0%C6?$#C
M"8BXVQ@`@#3XFRS_'IT&2J!7BV9\##(H\WN*(`05#``/%3@`A]L5'QL1K8+B
MD\$`@*`'!@1!"7[``2,W`!U0``>P)=C%%\B&#!#Q-WZ0'KY&>CP@!JRQ"A+@
M"*OP00^37=RU!&2`:=FG!B2@@7]05MVU>W$D`RN@``,D``3U;23`&D*A9LEW
M)]=76VM7_Q`1P1>$P"\/,1)(@`,#0`4C0`X*,`-P<"TF`#H9U!-'``6W@44Z
M-0874`Z\I@>U508GL`K3YAE9<@R3<AH'P`-4@'0N``&YD@$J@%I1@`2L,33-
MHH"KQQ9+@@P0*`@[T%Q4$&P"$QN%H&S:!01+$`$>1GHJ4``&4`@FR&5HM4DK
M\"T.@`1.``1T,`*:=PW_@'QLA@S>4`$R4'@N4"RLUR.Y(A@2<``(YW4<4`X*
MP`7\X!+9$B5C,27FD!$G@`-4@`-(P"$9LP$R``0X\`4P=T.S0FW&$03B1'L9
M`![75V0=L`*CM0,\4B*_,A$0DE=*Q51U8#[8A5VK8%&G`XC;=?\!ZG)P>S``
M46`!BJA[C4@%&T`!&<$`0K`'=!``VO98F3A?6;=J:I``5%`#"@`!0?,'I#%>
M$D$WQU`E!:!_;2`&[60`%&`$>0"+BN8HDU4%9U`N<U``FS0!(XAR!S`"[S<"
M+E!L7=@UA)(316`-!B``-K9V:%A:5*`#!6@-(*`:02(DO&@;"8,,A+`#1+9+
M!7`!1$F42W"4,54(D^)Z5$".'/(%;E!(3@`P:Z$$['A>GT4%T"@,2G``^L-=
M=S8OU?!90,!F!G(`:E"&1'![`VE)NJ$N:N$`","07[`V.0`&/A!W#8`&54`6
M3#@%9'`^@[=10H!NV,4!&(8'3G``9*#_.0+"'K;@,<:A93)08Y)7!&2D`SH@
M`@A0`@3'"#EA21P2:NC&.=>@5&U`!0G@`6;0FJVI`JET!R[P15L7B$+P/P90
M`.=(!0@`?=Y@E6,03R8!1[6UE;8``IET!6D438&I`"&`=5TB%1Q0`T,XE6TG
M9(60*9R(`+6E`G6Y%U62`A/Y&&0!BU40417T:R/``O95$H@Y`#I`!#%88HHP
M><C@!Q>0`'C`28]`1C/I`0A`!L82(CLC'=(S+%AU.@B0FE300@O$0&5@2FHP
MFUY1F]LE!%<"`6*P`?@F=?/V,A<@1RL0$0:P`CV@E4&S"B`@2C@0?/V#*R6P
M`J6TB1B!EO`Y_P*,N1=88B.W4`!`0`5[4)>&I0!SX`5YD`46DBTN804V``8?
M4*+Z-`$=HPM%\)X'Q9A*8)"&(!40(9?ZV0,78!P*4`$#D&$"@"=941*%0'`K
MF0$98`$N0"F%L*!`H(*%<Z?*,P$%P`%?5`0LH%UC@*&"()`G4`91R@$T<7UF
M%`(DN@+%F5O3P0$3`'518&4,``7ZV&;340$)H`,>L(NQ9!XMX@<&4`$ML%$V
M=)_?4`(TD`91PBU-\1,8$(D><`4=X%Z?B4).,(0\4)*A)AJFJ``"T*EM<`+"
MT))E2@<3\`%D4']?0@C2X0<N@`5:H`9#0%?&U`9`8`;/LS5*PP%*@_^='/*G
MW"6HB;.B$W!:V#2"(#"7"<"H6/FH')8#$;`97X!P+2!U)``%)AI/(M$'E"(!
M#T<%0'`"\[1G/>@F;<0"U$D%;A`T?E$$'G-[`#"150!PW:($",!'1.!B)7!"
M#+`"#&D!,W&'0Z($.>$`!K`!A<0#%B`2)2`$^M<#=\`"0P,@Q/@'QN('#)M:
M`K`9<ZI=NM@>Y8`GXNJG@(JAB;(*2*`&0X@#+%`""G`!+?"N6H%>6KE(;H(N
M$'`"*G!&"`8#*Y``97E%1'-[&5!D`]`_.@,<V'DG(V&5SG4%(5`(2?0'<_`"
M$PE^D]4``,`!F=8!`@`"<,ES'^""0R@`*,?_&XM@#?\@!NYW!=JF:DBPACT0
M!;TI;T+1'#M@"RS@!C(0``+0N84@`-K5AO<!&[R2L^-JF\&CN1]P`D#0`RV@
M!R0``1?0`5S&"%C[B,9`'K1&1G2F`@)``L]9EH^55S3A`B,`>5^'&Z!B#N]Q
M=N-D9_,!7TWP`#Y@`A"&04>0MCTP`D@@;S.5.!F@!70P`.);&:]A'+`E`!U`
M@(.&#`YP`!.P![]T![*F!$9S.@SXN:$K`!PRI]H:!2ZP>,GQ+WU*KD!@KG'C
M!R20KF.@A=>W!SH0`KS[3EE+%.3!&I+X2SR0`2&P?\L:$;N"F;I)MA40IY"`
MG?3J`!R``.>8;RRP_R?'``(4X`489"$H4$978+LJ>5V860%\1`?TD[.U(&`G
M4`,$JP5@)1T.D0$>T`(]X`%2.EIZ1@A^(0&?VP9U@`#3,J>_"+7S@1%$LL!)
M>R7"T"5*8`%.T`$AQ@(7H`(M,`$9_(F^VT;(P+]3B[\JR`,Z4,>/!2S_(F?C
M!*`<<"_-$8]"P%(#8&<,<Q'H-@.&ED$/X`$]H`)+\%CK-RU%8`#MUT=ND%#$
M$00N4`%`\'YZX#T&85%D-`8#T`)VY@*9I8A(\;ECT`8!VH5_H'$;A02UD"-'
M2ZZ!"ARGP0@"=@$$)0.K\XD8C)5XO$B,4!CE4`('(+()4`97$,C+.A)"`?^`
M4ZL",G`%.#`$%)!#,?(U&;`!VM4"(2`&*W<1$8",8,`&28H&\>L$%.@)Y^(7
M$2"I8$8'6/`%L>23,.()!_`^99J.84>(YP,!7T"&`]`#6M";U1`CD18!G]L!
M`8``1T/`[%7#,)(II`()K0L$Q0H<$;`#KD(&+##""1`%/.#,&3P&["8/0I8,
M1=`$3]<#\%G'GV0Q?<`!!5`&9A0`*\`"#G!LS@);Q]15X<L"T$()%,`'>HD&
M5R!H5[0(`^0&Z9L`=8`YCP8M)_8S)[`"BX4'6C`$G"4@.[`$6(`'.H`'>S`!
M7P`#4*,7(N$`%F`'5,#,4$""+CD`P1AO,1(MO/+_@`[``AZ`TH+*N+>2`V*@
M!3X->77,")X%9A-``0J0*HR'`*Y6AC(P`50G'[KQ`:<<H3)`!_PU6$G#`B*,
M`[_4`C5@L%(3"7U``&D0=UB]`"^[,X-P8DO<`5TE`A.0`9E##B2`!'/<!E?0
M`B*PIUXC(!"00C40H?OG!GJ`!-"C.>U$`K?XW`)`-X7P/OGJ7DV=WJOX)Q!`
M!D@0=&WPV-E9)?!;I@,P1QF<OBMHVGLV'BZ@!^BW2\NZDL/Q#S&L!<'956U0
M`R,P`EK4!O6X!TZ`6^B&G<!`!F>PV_A<`8\&W'MF`!:P`BVT!WO@`36P`2O@
M!",0!4:]2_R%9Z\C($>S_]Q^1<6T:^(H/@%/I0:&FLM@+'.",`0>4&Y$X`1.
M,%5(O@'''7;`\H%@%J@>`MGN`@'WM$D#$`#/;`!ZH`(!H`<&,*"'T*8C$``!
M('Q7)DN<HP0<(`0K@`,_2@6LQ$HRT`%M0`0"8`$4]SV4X`<JQP<^@`8+L,G@
M<A%2BP3(M0<MU5*[M.@M8`8A<`)XQLD]4J^;D5A$@'Y^]-RDIU%4W*"U]P^E
M*P)G1`==M4N;M.@RH&%A5WSN#69EL`3&(>5N)I!JF$MM8,>-8#MZ8'LF6PL2
M($H;8.2*.RYH7B\W-005X`0XL$M^5`=8(`!?H`#1`@-MN^=0X`!,\.=2,`-Z
MY?]%P1W8,J9"3N`!^^-+,L`#>C`$1'=L=Y(1,GX9$+$#<DRM9O37H<OLZ(X`
M8O#1A(``4;!+9$[FJ+[H(B`$WVQ?C"T"6O`#B=/K;%(L$W!`5CP>-FD2_+VE
M<=)C/^@KZT0H$*``8A#RT+,9NU(">34J\7(T#(`"/J`!88?RN#TLL'T!0[`$
M/\#MJ`$MH8$CB9`O$E`L$+`$0U``1)\"0Y`!''`T6VL($7`U)``#U)4U'##U
M4Y\Y$5`$02,!#.`"+I`YQN"_`</%0U\`2Z`;K`X?.GH1GC`O'')QX<$C#A(D
M\S+WML%(>H$1RT4@$S9:4AN%@(,5X943\X)B2&%LG>O_"47'\SVHIGA_C&C8
M3F5C)OQ+?M*[,Q05`3`P]YH_]V1S]0R@&"=V-0`(&V6<+TX/$)[1-;SR*Z^Q
M]O,,'>#1@W6A%UVJ+JNP$AF/;(<2+W5C#I'V/1:.+(&?D[>_"O-B(R"`LH`3
M'ZRG(HJ-71\0/0"(%'"K.(.`7?+V29NO^9O19GJ1:D=3='Y1"PRXTB4Q*8)P
M5:GV(SV('K>/(]+((#QR]\:P)"5A_Q95#A#BX7L""$H."D5^($4..45_C(V-
M?DHY.7Y%$@Y%F!\@(!^:F(*.?HY_HGZFG4I%?4H?#`R='PJNE8I]HPP.J9N[
MO)L1$(60$D6"2I9%.:.3A62%_X42C)4,JK2CCCL[?9NB18>VC4%!.W\[$!#B
MY-CA.1(1[A'0UO*-?1\.$46HA0[SC!+_^39IPD8P6PXR[APELY9#7)!_.?J4
M("-!4I`(,,R!F*1I5(02$105'%ENQZ%A$I0P.*DH7J-)(/KD4,(J1X1^.'/J
MW,FSI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K6+-JW<JU*U)3ID@!
M]<-/ZZ(_A;RJ_1I,[-JW<./F%$65KMR[7^WNI)0V:M]1E/3B'=QODA\*,WI2
M0GSVJ1\#"MPV4C"#PI^%A(-24J!@D($Y@PHIH93#P#(%D!T,XJQ:P6/.G4,7
M(32'C/^!+E":-)GM`"P_U6E5W^,RPY)J4XAXV_.,W+4$,A3\!$'K@$()S@:*
M$*@.9O8^3`ZX4"`3N7%FGH=7S_E#)O0<UKU3^^G,>1B%['.\O__C`#0B`]$I
MT,034%#``"&%<(;)?H6`-A$78+1G0&]^*"+<>\TP,-\?KBD`W1\4$))("=DA
M`D`.K>5G0':=,?$>:N<!I00%6[SP0@H$H(#"%@!H`$8<;,RQA7``//!`''/0
M@,(#&+Q0(P!)+DG`%#ZDD`(*+X"1PA%G:("!D"^@8(`7-J+@P(1SQ($"'TPD
ML:,7,\RQ)@$:\.&%DB\\X`4?E0'P@A<Y`+"%%Q30\.<<&!C_P`0;&J2!(P$Q
MR/$"%TR@$`<%3!#PYPSFQ3@790!`R@<7;!CP@)<$/```!5.H-@<;,V#`1PQ\
M&```$W$0,`,;&`#P00I>3`%`=3%XP008!&*`P18IS#&%!B@`4$0*%,PV@P]S
M:*!!$L/*H0%G&@3[@`%;8$"`%U#$`,!G!/A``0`S])?"#%O,P(4!&LBQJP(Q
MQ,!&#)"M""\`8&R1GV">]C,?!1A00`";=OH`!0!=8)"$N60][("F&*2QQ:EQ
M%$&CGSK*@0$8,/A9)05/E!"#K!K\P<25*82WW7P/].<%%P08@$(*7'R,@@9L
M./``8AA<1\.Y6SC*1&DQ//""#V#<_ZL!#6!H,$>_/B"HP18^S`"OJG\EG%,1
M<S#A\*@:?%;""VQP04/<@X"!`K\/Q!"R:GQ<PJP&ERB0J=@I:]#$&25PT04?
M&OBA00K,%N$EAQ3$X<<,J#KP,PU^,R$M"F1`D80$!GB[J@],:&`M$Z[-D(0#
M7[]K0+]Q$(*!'`H00$##"LQ=EMEG(^IP'$R\$&()^<;*!VJJ>?$X'ZG.,8<!
M<5PR]`,*4+`Q!10T>^,!4X#!!!<``*``HUNHSC.">;RK0:::3\'&M$.O.Z3K
MY,GQ,AAI*&#P?$.:2,Y2\`(R]`U24V`"[&@P`Q30*4170ACPK$&6>,VA9@"(
ME@-B4+-]/?^F"&"@@1<>D"T4R(%\(2).\0RFJU>A8`H`\T(*F!`#/[!!@YFZ
M'&@<,(,XB!`,!*"`$KP$+0"DH&H&2($22@"&7&B`"RA@@QP<L"P:S,%/*8`!
MY)RG`!F"80XSD`,*.!A%1-E-?Y&9($Z0LYE!K$8!._R,&\$@/AK`9S7`F<V$
MA%.($"F@0#"X#FK`>"9*`(<"9NI,"?+AQAE`9X\&2,4P!`%'X7P&#)R9@0'(
M($A,'&9%JNF.=LA""%TA0HTYX0==CO.).=#D$IZ!EOXN@8D$(8@L9^H0/]IS
M@.D%\A(3PD2)DO,N!^!B&(OP#&NX\0$E_($F?P#E)M%$@3Y`1@(0,*!E@GHC
,HD6X!CR7,$4@```[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
